The paper reports the screening results of two metal-based antineoplastic drugs with mutagenic
potential, such as Romcis (trademark of Cisplatinum, produced in Romania) and diphenylantimony(III)
diisopropyldithiophosphate (PADTF). Their effects were compared with those induced by
Cyclophosphamide. Two mutagenicity tests, the SOS Chromotest and cytogenetic analysis were
applied. The tests were carried out with or without metabolic activation (addition of S9-mix), either in E.
coli PQ 37 cultures, using four doses (0.3, 3, 30 and 300 pmol compound/assay) for the SOS
Chromotest or in leukocyte cultures using 0.3 mM from each compound, for cytogenetics. The dose-
response relationships and SOSIP values revealed an indirect mutagenic potential for
Cyclophosphamide, amplified by S9 mix in bacterial cultures and an antiproliferative, clastogenic effect
on lymphocytes. For Romcis and diphenylantimony(III) diisopropyldithiophosphate, a significant positive
response by SOS Chromotest was recorded, which correlated with increased frequencies of
chromosomal aberrations.
